LON:SNG

Synairgen Share Forecast, Price & News

GBX 105.10
-4.90 (-4.45 %)
(As of 05/7/2021 05:08 PM ET)
Add
Compare
Today's Range
104
113.64
50-Day Range
106.20
173
52-Week Range
32.71
260
Volume1.94 million shs
Average Volume2.30 million shs
Market Capitalization£210.11 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SNG News and Ratings via Email

Sign-up to receive the latest news and ratings for Synairgen and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-23-80512800
Employees14
Year FoundedN/A

Sales & Book Value

Annual Sales£79,000.00
Cash FlowGBX 6.43 per share
Book ValueGBX 7.70 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap£210.11 million
Next Earnings Date5/24/2021 (Estimated)
OptionableNot Optionable

Headlines

See More Headlines
Synairgen logo

About Synairgen

Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-Ã), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-Ã that is in Phase-II clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold and flu; and LOXL2 inhibitor, which has completed Phase I clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) and non-alcoholic fatty liver diseases. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor; and a strategic collaboration with Parexel Biotech on pivotal Phase III trial for the study of inhaled COVID-19 treatment. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

MarketRank

Overall MarketRank

0.40 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Synairgen (LON:SNG) Frequently Asked Questions

What stocks does MarketBeat like better than Synairgen?

Wall Street analysts have given Synairgen a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Synairgen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Synairgen's next earnings date?

Synairgen is scheduled to release its next quarterly earnings announcement on Monday, May 24th 2021.
View our earnings forecast for Synairgen
.

How were Synairgen's earnings last quarter?

Synairgen plc (LON:SNG) released its earnings results on Tuesday, September, 29th. The company reported ($3.11) earnings per share (EPS) for the quarter.
View Synairgen's earnings history
.

How has Synairgen's stock been impacted by COVID-19 (Coronavirus)?

Synairgen's stock was trading at GBX 21.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SNG stock has increased by 393.4% and is now trading at GBX 105.10.
View which stocks have been most impacted by COVID-19
.

Who are Synairgen's key executives?

Synairgen's management team includes the following people:
  • Mr. Richard Marsden, CEO, MD & Exec. Director (Age 53, Pay $289k)
  • Mr. John Ward, Fin. Director, Company Sec. & Exec. Director (Age 59, Pay $226k)
  • Dr. Phillip David Monk, Chairman of Scientific Advisory Board, Chief Scientific Officer & Exec. Director (Age 52, Pay $208k)
  • Prof. Donna Davies, Co-Founder & Member of Scientific Advisory Board
  • Prof. Ratko Djukanovic, Co-Founder & Member of Scientific Advisory Board

Who are some of Synairgen's key competitors?

What other stocks do shareholders of Synairgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Synairgen investors own include Alibaba Group (BABA), Yamana Gold (YRI), Eldorado Gold (ELD), Ocado Group (OCDO), Polo Resources (POL), Silvercorp Metals (SVM), W Resources (WRES), Associated British Foods (ABF), Ariana Resources (AAU) and First Majestic Silver (AG).

What is Synairgen's stock symbol?

Synairgen trades on the London Stock Exchange (LON) under the ticker symbol "SNG."

How do I buy shares of Synairgen?

Shares of SNG and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Synairgen's stock price today?

One share of SNG stock can currently be purchased for approximately GBX 105.10.

How much money does Synairgen make?

Synairgen has a market capitalization of £210.11 million and generates £79,000.00 in revenue each year.

How many employees does Synairgen have?

Synairgen employs 14 workers across the globe.

What is Synairgen's official website?

The official website for Synairgen is www.synairgen.com.

Where are Synairgen's headquarters?

Synairgen is headquartered at Southampton General Hosp, Tremona Road, SOUTHAMPTON, SO16 6YD, United Kingdom.

How can I contact Synairgen?

Synairgen's mailing address is Southampton General Hosp, Tremona Road, SOUTHAMPTON, SO16 6YD, United Kingdom. The company can be reached via phone at +44-23-80512800.


This page was last updated on 5/7/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.